Deferred registration: Fortrea code: 780587
| ISRCTN | ISRCTN17866568 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN17866568 |
| Integrated Research Application System (IRAS) | 1013458 |
| Sponsor | Lundbeck (Denmark) |
| Funder | H. Lundbeck A/S |
- Submission date
- 09/07/2026
- Registration date
- 09/07/2026
- Last edited
- 09/07/2026
- Recruitment status
- No longer recruiting
- Overall study status
- Deferred
- Condition category
- Other
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date.
Contact information
Dr Jonathan Ackroyd
Principal investigator, Public, Scientific
Principal investigator, Public, Scientific
Drapers Yard, Marshall St, Holbeck
Leeds
LS11 9EH
United Kingdom
| Phone | +44 1133013645 |
|---|---|
| Jonathan.Ackroyd@fortrea.com |
Study information
| Primary study design | Interventional |
|---|---|
| Allocation | N/A: single arm study |
| Masking | Open (masking not used) |
| Control | Uncontrolled |
| Assignment | Single |
| Purpose | Metabolism and bioavailability |
| Scientific title | Deferred registration: Fortrea code: 780587 Full scientific title to be added on or before the deferral expiry date |
| Study objectives | The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date. |
| Ethics approval(s) |
Approved 04/03/2026, London - Brent Research Ethics Committee (Health Research Authority, 2 Redman Place, Stratford, London, E20 1JQ, United Kingdom; no telephone number provided; brent.rec@hra.nhs.uk), ref: 26/LO/0019 |
| Health condition(s) or problem(s) studied | The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date. |
| Intervention | The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date. |
| Intervention type | Drug |
| Phase | Phase I |
| Drug / device / biological / vaccine name(s) | The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date |
| Primary outcome measure(s) |
|
| Key secondary outcome measure(s) | |
| Completion date | 20/07/2027 |
Eligibility
| Participant type(s) | |
|---|---|
| Age group | Adult |
| Lower age limit | 35 Years |
| Upper age limit | 55 Years |
| Sex | All |
| Target sample size at registration | 15 |
| Key inclusion criteria | The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date. |
| Key exclusion criteria | The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date. |
| Date of first enrolment | 08/07/2026 |
| Date of final enrolment | 14/08/2026 |
Locations
Countries of recruitment
- United Kingdom
- England
Study participating centre
Fortrea Clinical Research Unit
Drapers Yard, Marshall St, Holbeck
Leeds
LS11 9EH
England
Leeds
LS11 9EH
England
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|
Editorial Notes
09/07/2026: Trial's existence confirmed by London - Brent Research Ethics Committee.